PE firm Ampersand acquires German CDMO Vibalogics

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/mikdam)
(Image: Getty/mikdam)

Related tags: CDMO, Ampersand Capital, PE, acquistion, development, Manufacturing, Gmp, Gene therapy

The private equity firm Ampersand Capital has acquired Vibalogics with plans to increase development and manufacturing capabilities for complex viral products.

Through the acquisition, the middle market private equity (PE) firm will work to expand Vibalogics capabilities to meet the industry’s demand through investments in additional process development and manufacturing capabilities.

The German contract development and manufacturing organization (CDMO) provides services for biopharmaceutical companies working to develop oncolytic viral therapies, gene therapies, and vaccines, specifically focusing on viruses, live bacteria, and aseptic processing.

Vibalogic’s 27,000 square-foot facility in Cuxhaven, Germany has four independent good manufacturing practice (GMP) production suites, and all laboratories meet BSL-2 standards.

David Anderson, general partner at Ampersand explained, “Given the exciting developments within the complex virus market this is an excellent time for an investor with deep experience in the viral vector contract manufacturing sector to partner with the company.”

Stefan Bayer, CEO of Vibalogics, said in a statement that with this partnership Vibalogics will also be able to strengthen and expand its position in the US and European markets.

Ampersand’s current portfolio includes other service providers such as Brammer Bio, Avista Pharma, Bioventus, MedPharm, and KeyBiologics.

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Import Risks & Clinical Supply Depots

Import Risks & Clinical Supply Depots

Catalent Pharma Solutions | 07-Nov-2018 | Case Study

A sponsor running a clinical trial in Israel arranged to ship their clinical trial product from Europe to a depot in Israel. With the protocol based in...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars